Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.

Antoniazzi F, Bertoldo F, Lauriola S, Sirpresi S, Gasperi E, Zamboni G, Tatò L

The Journal of clinical endocrinology and metabolism1 Jun 1999Cited by 23 (Europe PMC)

PMID10372699DOI10.1210/jcem.84.6.5791PepBankPUB-10372699

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialSafety outcome
In girls with precocious puberty, lumbar BMDv decreased during triptorelin alone.
In plain wordsIn girls with early puberty, spine bone density decreased during triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseAbsolute lumbar BMDv without calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 2 yrAs given in this study (human).
Source sentences
Summary
Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA).
2 context sentences(design, population, supporting numbers)
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
Report a problemFND-1037269901
02HumanRandomized controlled trialSafety outcome
In girls with precocious puberty, lumbar BMDv score for chronological age decreased during triptorelin alone.
In plain wordsIn girls with early puberty, spine bone density score for chronological age decreased during triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseLumbar BMDv score for chronological age without calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 2 yrAs given in this study (human).
Source sentences
Summary
Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA).
2 context sentences(design, population, supporting numbers)
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
Report a problemFND-1037269902
03HumanRandomized controlled trialSafety outcome
In girls with precocious puberty, lumbar BMDv score for bone age decreased during triptorelin alone.
In plain wordsIn girls with early puberty, spine bone density score for bone age decreased during triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseLumbar BMDv score for bone age without calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 2 yrAs given in this study (human).
Source sentences
Summary
Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA).
2 context sentences(design, population, supporting numbers)
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
Report a problemFND-1037269903
04HumanRandomized controlled trialSafety outcome
In girls with precocious puberty, lumbar BMDv decreased during the first year of triptorelin before calcium supplementation.
In plain wordsIn girls with early puberty, spine bone density decreased during the first year of triptorelin before calcium supplementation.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseAbsolute lumbar BMDv before delayed calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Group B showed the same behavior during the first year, but this trend was reversed in the second year, when calcium supplementation was added to GnRHa treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA).
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
Report a problemFND-1037269904
05HumanRandomized controlled trialSafety outcome
In girls with precocious puberty, lumbar BMDv chronological-age score decreased during triptorelin before delayed calcium supplementation.
In plain wordsIn girls with early puberty, spine bone density chronological-age score decreased during triptorelin before delayed calcium supplementation.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseLumbar BMDv chronological-age score before delayed calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Group B showed the same behavior during the first year, but this trend was reversed in the second year, when calcium supplementation was added to GnRHa treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA).
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
Report a problemFND-1037269905
06HumanRandomized controlled trialSafety outcome
In girls with precocious puberty, lumbar BMDv bone-age score decreased during triptorelin before delayed calcium supplementation.
In plain wordsIn girls with early puberty, spine bone density bone-age score decreased during triptorelin before delayed calcium supplementation.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseLumbar BMDv bone-age score before delayed calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Group B showed the same behavior during the first year, but this trend was reversed in the second year, when calcium supplementation was added to GnRHa treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA).
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
Report a problemFND-1037269906

Studies that did not test the peptide alone9

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome
In girls receiving triptorelin, delayed calcium supplementation reversed the lumbar BMDv decline during the second year.
In plain wordsIn girls receiving triptorelin, delayed calcium supplementation reversed the spine bone density decline during the second year.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAbsolute lumbar BMDv after delayed calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Group B showed the same behavior during the first year, but this trend was reversed in the second year, when calcium supplementation was added to GnRHa treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA).
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1037269907
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome
In girls receiving triptorelin, delayed calcium supplementation reversed the lumbar BMDv chronological-age score decline.
In plain wordsIn girls receiving triptorelin, delayed calcium supplementation reversed the spine bone density chronological-age score decline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseLumbar BMDv chronological-age score after delayed calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Group B showed the same behavior during the first year, but this trend was reversed in the second year, when calcium supplementation was added to GnRHa treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA).
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1037269908
09HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome
In girls receiving triptorelin, delayed calcium supplementation reversed the lumbar BMDv bone-age score decline.
In plain wordsIn girls receiving triptorelin, delayed calcium supplementation reversed the spine bone density bone-age score decline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseLumbar BMDv bone-age score after delayed calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Group B showed the same behavior during the first year, but this trend was reversed in the second year, when calcium supplementation was added to GnRHa treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA).
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1037269909
10HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome
In girls with precocious puberty, lumbar BMDv increased during triptorelin with calcium from treatment onset.
In plain wordsIn girls with early puberty, spine bone density increased during triptorelin with calcium from treatment onset.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAbsolute lumbar BMDv with immediate calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Group C showed an increase in absolute BMDv levels and in SD score for CA and BA.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1037269910
11HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome
In girls with precocious puberty, lumbar BMDv chronological-age score increased during triptorelin with immediate calcium.
In plain wordsIn girls with early puberty, spine bone density chronological-age score increased during triptorelin with immediate calcium.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseLumbar BMDv chronological-age score with immediate calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Group C showed an increase in absolute BMDv levels and in SD score for CA and BA.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1037269911
12HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome
In girls with precocious puberty, lumbar BMDv bone-age score increased during triptorelin with immediate calcium.
In plain wordsIn girls with early puberty, spine bone density bone-age score increased during triptorelin with immediate calcium.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseLumbar BMDv bone-age score with immediate calcium
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Group C showed an increase in absolute BMDv levels and in SD score for CA and BA.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1037269912
13HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome
In girls with precocious puberty, lumbar BMDv variation favored triptorelin with immediate calcium over triptorelin alone at 24 months.
In plain wordsIn girls with early puberty, spine bone density change favored triptorelin with immediate calcium over triptorelin alone at 24 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAbsolute lumbar BMDv variation versus no calcium
Study
n: not reported in source
Comparator
Triptorelin alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
BMDv variations (expressed as absolute values, SD score for CA, and SD score for BA) became statistically significant at 24 months between groups C and A (P = 0.036, P = 0.032, and P = 0.025, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA).
Summary · context
Group C showed an increase in absolute BMDv levels and in SD score for CA and BA.
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1037269913
14HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome
In girls with precocious puberty, chronological-age BMDv score variation favored triptorelin with immediate calcium over triptorelin alone at 24 months.
In plain wordsIn girls with early puberty, chronological-age bone density score change favored triptorelin with calcium over triptorelin alone at 24 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseLumbar BMDv chronological-age score variation versus no calcium
Study
n: not reported in source
Comparator
Triptorelin alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
BMDv variations (expressed as absolute values, SD score for CA, and SD score for BA) became statistically significant at 24 months between groups C and A (P = 0.036, P = 0.032, and P = 0.025, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA).
Summary · context
Group C showed an increase in absolute BMDv levels and in SD score for CA and BA.
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1037269914
15HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialSafety outcome
In girls with precocious puberty, bone-age BMDv score variation favored triptorelin with immediate calcium over triptorelin alone at 24 months.
In plain wordsIn girls with early puberty, bone-age bone density score change favored triptorelin with calcium over triptorelin alone at 24 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseLumbar BMDv bone-age score variation versus no calcium
Study
n: not reported in source
Comparator
Triptorelin alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
BMDv variations (expressed as absolute values, SD score for CA, and SD score for BA) became statistically significant at 24 months between groups C and A (P = 0.036, P = 0.032, and P = 0.025, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA).
Summary · context
Group C showed an increase in absolute BMDv levels and in SD score for CA and BA.
Summary · context
Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr.
Summary · context
group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1037269915

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.